Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
Abstract Background Transcription factor c-Myc plays a critical role in various physiological and pathological events. c-Myc gene rearrangement is closely associated with multiple myeloma (MM) progression and drug resistance. Thereby, targeting c-Myc is expected to be a useful therapeutic strategy f...
Main Authors: | Ruosi Yao, Menghui Zhang, Jian Zhou, Linlin Liu, Yan Zhang, Jian Gao, Kailin Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-05-01
|
Series: | Cell Communication and Signaling |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12964-022-00868-6 |
Similar Items
-
Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma
by: Shihao Li, et al.
Published: (2024-04-01) -
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
by: Alejandra Ortiz-Ruiz, et al.
Published: (2021-04-01) -
Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway
by: Xiaotang Di, et al.
Published: (2024-01-01) -
Review: proteins c-Myc and Myc-nick as potential targets for the melignant melanoma treatment
by: G. Maryniuk, et al.
Published: (2023-07-01) -
Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
by: Omar Faruq, et al.
Published: (2022-03-01)